HRP20200085T1 - Topljivi cd33 za liječenje mijelodisplastičnih sindroma (mds) - Google Patents

Topljivi cd33 za liječenje mijelodisplastičnih sindroma (mds) Download PDF

Info

Publication number
HRP20200085T1
HRP20200085T1 HRP20200085TT HRP20200085T HRP20200085T1 HR P20200085 T1 HRP20200085 T1 HR P20200085T1 HR P20200085T T HRP20200085T T HR P20200085TT HR P20200085 T HRP20200085 T HR P20200085T HR P20200085 T1 HRP20200085 T1 HR P20200085T1
Authority
HR
Croatia
Prior art keywords
seq
amino acid
acid sequence
fusion protein
extracellular domain
Prior art date
Application number
HRP20200085TT
Other languages
English (en)
Inventor
Alan F. List
Sheng WEI
Original Assignee
H. Lee Moffitt Cancer Center And Research Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lee Moffitt Cancer Center And Research Institute, Inc. filed Critical H. Lee Moffitt Cancer Center And Research Institute, Inc.
Publication of HRP20200085T1 publication Critical patent/HRP20200085T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)

Claims (15)

1. Kimerni rekombinatni fuzijski protein, koji sadrži: (a) kombinaciju od barem dva S100A9-vezujuća dijela odabrana od skupine koja se sastoji od izvanstanične domene humanog CD33, izvanstanične domene receptora nalik tollu 4 (TLR4) i izvanstaničnu domenu receptora krajnjih produkata uznapredovale glikacije (RAGE); i (b) Fc regiju imunoglobulina.
2. Fuzijski protein prema zahtjevu 1, koji sadrži formulu odabranu od skupine koja se sastoji od: eCD33 - eTLR4 - Fc, eCD33 - eRAGE - Fc, eTLR4 - eRAGE - Fc, eRAGE - eTLR4 - Fc, eCD33 - eTLR4 - eRAGE - Fc, eCD33 - eRAGE - eTLR4 - Fc, eTLR4 - eCD33 - eRAGE - Fc, eRAGE - eCD33 - eTLR4 - Fc, eTLR4 - eRAGE - eCD33 - Fc i eRAGE - eTLR4 - eCD33 - Fc, pri čemu “eCD33” sadrži izvanstaničnu domenu humanog CD33, pri čemu “eTLR4” sadrži izvanstaničnu domenu od TLR4, pri čemu “eRAGE” sadrži izvanstaničnu domenu od RAGE, pri čemu “Fc” sadrži Fc regiju imunoglobulina, i pri čemu “-” se sastoji od peptidnog veznika ili peptidne veze.
3. Fuzijski protein prema zahtjevu 1 ili 2, koji dalje sadrži biotin akceptor peptid koji može biti biotiniliran s biotin ligazom (BirA) u prisutnosti biotina i ATP.
4. Fuzijski protein prema zahtjevu 3, pri čemu biotin akceptor peptid sadrži sekvencu aminokiselina SEQ ID NO:7, ili sekvencu aminokiselina koja ima barem 90 % identičnosti s SEQ ID NO:7.
5. Fuzijski protein prema bilo kojem od zahtjeva 1 do 4, pri čemu izvanstanična domena humanog CD33 sadrži samo varijabilnu regiju.
6. Fuzijski protein prema bilo kojem od zahtjeva 1 do 5, pri čemu izvanstanična domena humanog CD33 sadrži sekvencu aminokiselina SEQ ID NO:1, ili sekvencu aminokiselina koja ima barem 90 % identičnosti s SEQ ID NO:1, poželjno pri čemu izvanstanična domena humanog CD33 sadrži sekvencu aminokiselina SEQ ID NO:2.
7. Fuzijski protein prema zahtjevu 5, pri čemu varijabilna regija humanog CD33 sadrži sekvencu aminokiselina SEQ ID NO:3, ili sekvencu aminokiselina koja ima barem 90 % identičnosti s SEQ ID NO:3, poželjno pri čemu varijabilna regija humanog CD33 sadrži sekvencu aminokiselina SEQ ID NO:4.
8. Fuzijski protein prema bilo kojem od zahtjeva 1 do 7, pri čemu izvanstanična domena humanog TLR4 sadrži sekvencu aminokiselina SEQ ID NO:5, ili sekvencu aminokiselina koja ima barem 90 % identičnosti s SEQ ID NO:5.
9. Fuzijski protein prema bilo kojem od zahtjeva 1 do 8, pri čemu izvanstanična domena humanog RAGE sadrži sekvencu aminokiselina SEQ ID NO:6, ili sekvencu aminokiselina koja ima barem 90 % identičnosti s SEQ ID NO:6.
10. Multimerski kompleks koji sadrži dva ili više fuzijskih proteina prema bilo kojem od zahtjeva 1 do 9 konjugiranih na ključnu molekulu ili česticu.
11. Multimerski kompleks prema zahtjevu 10, pri čemu je ključna molekula streptavidin, pri čemu su dva ili više fuzijskih proteina biotinilirani.
12. Multimerski kompleks prema zahtjevu 10, pri čemu je ključna molekula liposom koji sadrži antitijela koja specifično vežu dva ili više fuzijskih proteina, poželjno pri čemu antitijela specifično vežu biotin akceptor peptid.
13. Multimerski kompleks prema bilo kojem od zahtjeva 10 do 12, koji sadrži od 2 do 5 fuzijskih proteina konjugiranih na ključnu molekulu ili česticu.
14. Fuzijski protein prema bilo kojem od zahtjeva 1 do 9 ili multimerski kompleks prema bilo kojem od zahtjeva 10 do 13 za uporabu u liječenju bolesti ili stanja uzrokovanog ili pogoršanog S100A9 aktivnošću, koja sadrži primjenu sastava koji sadrži spomenuti fuzijski protein ili multimerski kompleks na subjektu kojemu je to potrebno.
15. Fuzijski protein ili multimerski kompleks za uporabu prema zahtjevu 14, pri čemu uporaba sadrži liječenje infekcije, sepse, ili njihove kombinacije, autoimune bolesti, reumatoidnog artritisa, raka ili mijelodisplastičnog sindroma (MDS) kod subjekta.
HRP20200085TT 2013-07-05 2014-07-03 Topljivi cd33 za liječenje mijelodisplastičnih sindroma (mds) HRP20200085T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361843274P 2013-07-05 2013-07-05
US201461930798P 2014-01-23 2014-01-23
US201461931366P 2014-01-24 2014-01-24
US201461978009P 2014-04-10 2014-04-10
PCT/US2014/045444 WO2015003149A2 (en) 2013-07-05 2014-07-03 Soluble cd33 for treating myelodysplastic syndromes (mds)
EP14819813.8A EP3016512B1 (en) 2013-07-05 2014-07-03 Soluble cd33 for treating myelodysplastic syndromes (mds)

Publications (1)

Publication Number Publication Date
HRP20200085T1 true HRP20200085T1 (hr) 2020-06-26

Family

ID=52144293

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200085TT HRP20200085T1 (hr) 2013-07-05 2014-07-03 Topljivi cd33 za liječenje mijelodisplastičnih sindroma (mds)

Country Status (19)

Country Link
US (3) US10344072B2 (hr)
EP (2) EP3711484A1 (hr)
JP (2) JP6673200B2 (hr)
AU (3) AU2014285079A1 (hr)
BR (1) BR112015032763A2 (hr)
CA (1) CA2917485A1 (hr)
CY (1) CY1122813T1 (hr)
DK (1) DK3016512T3 (hr)
ES (1) ES2777227T3 (hr)
HR (1) HRP20200085T1 (hr)
HU (1) HUE048842T2 (hr)
LT (1) LT3016512T (hr)
MX (1) MX377002B (hr)
PL (1) PL3016512T3 (hr)
PT (1) PT3016512T (hr)
RS (1) RS59925B1 (hr)
SI (1) SI3016512T1 (hr)
SM (1) SMT202000118T1 (hr)
WO (1) WO2015003149A2 (hr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3016512T1 (sl) * 2013-07-05 2020-07-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Topni CD33 za zdravljenje mielodisplastičnih sindromov (MDS)
US10688077B2 (en) 2015-02-26 2020-06-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
WO2016179036A1 (en) * 2015-05-01 2016-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. S100a9 levels for predicting lenalidomide and erythropoietin responsiveness
US10488411B2 (en) * 2015-05-01 2019-11-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
EP3379248B1 (en) * 2015-11-18 2020-09-23 Tokyo Ohka Kogyo Co., Ltd. Arginase activity measurement method, arginase activity detection kit, arginase-related disease detection kit, and arginase inhibitor or active agent screening method
EP3802582A4 (en) * 2018-06-07 2022-06-15 Palleon Pharmaceuticals Inc. MULTIMERIC PROTEINS FOR DETECTING A CARBOHYDRATE AND/OR TREATMENT OF A SIGLEC MEDIATED DISORDER
EP3807423A4 (en) * 2018-06-13 2022-04-27 The Council Of The Queensland Institute Of Medical Research Viral detection assay
EP3849565A4 (en) * 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
CN111840561B (zh) * 2020-08-11 2022-03-04 大连医科大学附属第一医院 S100a9抑制剂在制备治疗胰腺炎的药物中的应用
WO2022152902A1 (en) * 2021-01-18 2022-07-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
WO2022216157A1 (en) * 2021-04-09 2022-10-13 Stichting Radboud Universiteit Off the shelf proximity biotinylation enzyme
CN116377048B (zh) * 2022-04-22 2024-05-07 广州市妇女儿童医疗中心 S100a8/a9复合体在诊治先天性巨结肠中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (hr) 1968-10-17 1970-08-24
US5620689A (en) 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
ATE486937T1 (de) 1996-07-12 2010-11-15 Genentech Inc Chimärische heteromultimerische adhesine
US20040033603A1 (en) * 2002-08-19 2004-02-19 Lin Zhang Biotinylation of proteins
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
US7355008B2 (en) * 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8080245B2 (en) * 2004-08-04 2011-12-20 University Of Massachusetts Anti-pathogen immunoadhesins
US20060241040A1 (en) * 2005-04-06 2006-10-26 Alberto Visintin Methods of treating disorders associated with toll-like receptor 4 (TLR4) signalling
EP1736482A1 (en) * 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Recombinant trimeric 4-1BBL
TW200726776A (en) * 2005-07-29 2007-07-16 Friedrich Alexander University Of Erlangen Nuremberg CD33-specific single-chain immunotoxin and methods of use
US20080311122A1 (en) * 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
AU2007257683A1 (en) 2006-06-12 2007-12-21 Symphogen A/S Pan-cell surface receptor- specific therapeutics
US8841421B2 (en) 2007-04-26 2014-09-23 Active Biotech, Ab S100A9 interaction screening method
US8398977B2 (en) * 2007-06-14 2013-03-19 Galactica Pharmaceuticals, Inc. Rage fusion proteins
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
AU2011349049B2 (en) 2010-12-22 2016-08-11 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
SI3016512T1 (sl) * 2013-07-05 2020-07-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Topni CD33 za zdravljenje mielodisplastičnih sindromov (MDS)

Also Published As

Publication number Publication date
WO2015003149A3 (en) 2015-03-12
SMT202000118T1 (it) 2020-03-13
US20200055916A1 (en) 2020-02-20
MX2016000211A (es) 2016-07-08
AU2018205105A1 (en) 2018-07-26
EP3016512B1 (en) 2020-01-08
MX377002B (es) 2025-03-07
JP2020011979A (ja) 2020-01-23
PL3016512T3 (pl) 2020-09-07
US20160215038A1 (en) 2016-07-28
PT3016512T (pt) 2020-02-24
AU2018205105B2 (en) 2020-06-04
EP3711484A1 (en) 2020-09-23
JP2016523930A (ja) 2016-08-12
CA2917485A1 (en) 2015-01-08
ES2777227T3 (es) 2020-08-04
EP3016512A4 (en) 2017-01-11
DK3016512T3 (da) 2020-02-03
US11584787B2 (en) 2023-02-21
AU2014285079A1 (en) 2016-01-21
EP3016512A2 (en) 2016-05-11
WO2015003149A2 (en) 2015-01-08
LT3016512T (lt) 2020-03-10
HUE048842T2 (hu) 2020-08-28
CY1122813T1 (el) 2021-05-05
US10344072B2 (en) 2019-07-09
SI3016512T1 (sl) 2020-07-31
RS59925B1 (sr) 2020-03-31
JP6673200B2 (ja) 2020-03-25
BR112015032763A2 (pt) 2017-11-07
AU2020227092A1 (en) 2020-09-24
US20230348555A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
EA201490745A1 (ru) Полипептиды антител, которые вызывают антагонизм cd40l
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
JP2017533891A5 (hr)
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
PH12018502451A1 (en) Brain delivery protein
EP4434543A3 (en) Human igg1 fc region variants and uses thereof
HRP20210411T1 (hr) Jednoručni receptori fuzijskih proteina tipa i i tipa ii i njihove uporabe
MX375426B (es) Direccionamiento de antagonistas de citocinas.
WO2015069922A3 (en) Alk antibodies, conjugates, and chimeric antigen receptors, and their use
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
JP2017504577A5 (hr)
SI2802606T1 (en) Improves the transfer of healing molecules through the hematoencephalic barrier
JP2016527286A5 (hr)
FI3677591T3 (fi) Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b
HRP20151227T1 (hr) Sastavi i postupci uporabe za terapeutska protutijela
WO2013181087A3 (en) Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
HRP20212023T1 (hr) Modulokini temeljeni na il-15 i il-15ralpha sushi domeni
WO2015031673A3 (en) Cns-targetedconjugates of antibodies
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
HRP20231186T1 (hr) Modulacija imunoreceptora za liječenje raka i virusnih infekcija
WO2017060322A3 (en) Ptefb-inhibitor-adc
WO2013055058A3 (ko) 항체결합 펩타이드-페리틴 융합단백질 및 이의 용도
PE20130207A1 (es) Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
EA201691782A1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения